Related Experiment Video
Updated: Jan 19, 2026

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
Published on: June 9, 2023
ER-mediated anti-tumor effects of shikonin on breast cancer
Yang Yang1, Wenya Gao1, Shiying Tao1
1School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 100029, China.
Abstract:
Estrogen receptor (ER) is expressed in most Breast cancer (BC) patients. G protein-coupled estrogen receptor (GPER), which is a membrane-bound estrogen receptor, is associated with the tumor development and progression in BC. Shikonin (SK) is a natural compound that is known to have anti-tumor effects. This study aims to assess the effects of shikonin on the cell proliferation, cell cycle and cell apoptosis of BC and whether the effects are related to ER/GPER signaling pathway. The results demonstrated that shikonin inhibited the cellular proliferation of MCF-7 BC cells via G0/G1 arrest and apoptosis in concentration-dependent manner. The anti-proliferative effect of SK on SK-BR-3 BC cells was associated with apoptosis. Both ERα and GPER were expressed in MCF-7 cells, while ERα were negative and GPER were positive in SK-BR-3 cells. Furthermore, shikonin downregulated the expression of ERα and GPER, and this effect was not affected by the estrogen environment. In addition, shikonin downregulated the EGFR and p-ERK expression in MCF-7 and SK-BR-3, which was also not affected by the estrogen environment. EGFR and p-ERK were still suppressed by co-treatment with the selective GPER against G1 or antagonist G15. In conclusion, these results suggest that shikonin shows anti-tumor effects on MCF-7 and SK-BR-3 cells. The effects seem to be associated with EGFR/p-ERK downregulation via ERα and GPER inhibition.
Insights
Shikonin (SK) exhibits anti-tumor effects by inhibiting breast cancer (BC) cell proliferation and inducing apoptosis. These effects are linked to the downregulation of estrogen receptor alpha (ERα) and G protein-coupled estrogen receptor (GPER) signaling pathways.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Estrogen receptor (ER) is prevalent in breast cancer (BC).
- G protein-coupled estrogen receptor (GPER) influences BC tumor development.
- Shikonin (SK) is a natural compound with known anti-tumor properties.
Purpose of the Study:
- To investigate shikonin's effects on BC cell proliferation, cell cycle, and apoptosis.
- To determine if these effects involve the ER/GPER signaling pathway.
Main Methods:
- Assessed shikonin's impact on MCF-7 and SK-BR-3 BC cell lines.
- Analyzed cell proliferation, cell cycle arrest (G0/G1), and apoptosis.
- Examined the expression levels of ERα, GPER, EGFR, and p-ERK.
- Utilized GPER antagonist G15 to evaluate pathway involvement.
Main Results:
- Shikonin inhibited MCF-7 cell proliferation via G0/G1 arrest and apoptosis.
- Shikonin induced apoptosis in SK-BR-3 cells, reducing proliferation.
- Shikonin downregulated ERα and GPER expression in both cell lines, independent of estrogen levels.
- Shikonin suppressed EGFR and p-ERK expression, which was further confirmed by GPER antagonist treatment.
Conclusions:
- Shikonin demonstrates anti-tumor activity against MCF-7 and SK-BR-3 breast cancer cells.
- The anti-cancer effects are associated with the inhibition of ERα and GPER.
- Downregulation of the EGFR/p-ERK pathway mediated by ERα and GPER inhibition contributes to shikonin's efficacy.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Mitogens and the Cell Cycle
Drugs that Stabilize Microtubules
Inhibition of Cdk Activity
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Tumor Immunotherapy

